

**Remarks**

**Support for Amendments.** All changes are typographical errors and the foregoing amendments do not add new matter to the application for the following reasons.

The changes to page 9 correct the numbering of the figures, but do not add substantive content. The sequences identified as SEQ ID NOS: 7, 31, 95 and 95 were included in the specification as originally filed at pages 17, 19, 21, 43 and 57.

Respectfully submitted,



Timothy J. Gaul  
Attorney for Applicants  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date: August 14, 2001

Please send all future correspondence to:

US Patent Operations/ TJG  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

VERSION WITH MARKINGS TO SHOW CHANGES MADE

A, D: Single disulfide-bonded dimers. IgG1 antibodies typically have two disulfide bonds at the hinge region between the constant and variable domains. The Fc domain in Figures 2A 1A and 2D 1D may be formed by truncation between the two disulfide bond sites or by substitution of a cysteinyl residue with an unreactive residue (e.g., alanyl). In Figure 2A 1A, the Fc domain is linked at the amino terminus of the peptides; in 2D 1D, at the carboxyl terminus.

B, E: Doubly disulfide-bonded dimers. This Fc domain may be formed by truncation of the parent antibody to retain both cysteinyl residues in the Fc domain chains or by expression from a construct including a sequence encoding such an Fc domain. In Figure 2B 1B, the Fc domain is linked at the amino terminus of the peptides; in 2E 1E, at the carboxyl terminus.

At page 43, replace lines 1-4, with the following:

F<sup>1</sup>-Λ-YIGSR-Λ-RGD  
(SEQ ID NOS: 957, 31)  
YIGSR-Λ-RGD-Λ-F<sup>1</sup>  
(SEQ ID NOS: 957, 31)

At page 21, Table 6, lines 10-11, replace with the following:

**Table 6—Laminin-related peptide sequences**

Sequence/structure	SEQ ID NO:
YIGSRYIGSR [i.e., (YIGSR) <sub>2</sub> ]	128
YIGSRYIGSRYIGSR [i.e., (YIGSR) <sub>3</sub> ]	129
YIGSRYIGSRYIGSRYIGSR [i.e., (YIGSR) <sub>4</sub> ]	130
YIGSRYIGSRYIGSRYIGSRYIGSR [i.e., (YIGSR) <sub>5</sub> ]	131
IPCNNKGAHSVGLMWWMLAR	132
YIGSRREDVEILDVPDGR	133
RGDRGDYIGSRRGD	134
YIGSRYIGSRYIGSRYIGSRYIGSR	135
REDVEILDVYIGSRPDGR	<del>136</del> 95
YIGSRREDVEILDVPDGR	<del>137</del> 96

At page 57, replace the third paragraph, lines 15-17, with the following:

Two of the best peptides were

REDVEILDVYIGSRPDSGR (SEQ ID NO: ~~136~~95) and

YIGSRREDVEILDVPDSGR (SEQ ID NO: ~~137~~96).

13. The composition of matter of Claim 2 wherein the composition of matter comprises one or more sequences selected from Tables 3, 4, 5, and 6 (SEQ ID NOS: 22 to 94, 95, 96, 128 to ~~137~~135).

25. A composition of matter comprising an amino acid sequence selected from SEQ ID NOS: 95, 96, 132 to ~~137~~135.